Treatment with itepekimab resulted in a lower incidence of events indicating loss of asthma control and improved lung function in adults with moderate to severe asthma, according to new phase 2 data.

Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials. Regeneron and Sanofi are assessing the data and will discuss next steps ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies. AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former.

Itepekimab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement and is currently in clinical development programs for CRSwNP (phase 3), non-cystic fibrosis ...

Itepekimab met the primary endpoint in AERIFY-1, reducing COPD exacerbations, but failed in AERIFY-2 despite initial benefits. Lower-than-expected exacerbation rates, possibly due to the COVID-19 ...

Itepekimab Study. This phase II trial randomized 296 adult patients (mean age about 50) with moderate-to-severe asthma in equal numbers to the aforementioned four treatment arms.

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically . Tuesday, 02 January 2024 12:17 GMT. عربي ...

TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational ...

TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use ...